AbbVie reports positive Phase 3 Skyrizi data in Crohn’s disease

AbbVie presented new Phase 3 AFFIRM results for subcutaneous SKYRIZI in adults with moderately to severely active Crohn’s disease at the American College of Gastroenterology 2026 Annual Scientific Meeting on October 13, 2026. At week 24, endoscopic remission reached 35.8% with SKYRIZI versus 9.1% with placebo, while ulcer-free endoscopy reached 36.6% versus 9.1%. The findings support AbbVie’s applications seeking U.S. and European approval of a subcutaneous induction regimen, which remains under regulatory review.

The data add evidence for a patient-administered SKYRIZI induction option and could broaden the drug’s Crohn’s disease use if regulators approve it. No approval has been reported, so the commercial impact remains dependent on FDA and EMA decisions.

  • 1The AFFIRM study randomized 289 patients in a 2:1 ratio to subcutaneous risankizumab or placebo.
  • 2At week 24, endoscopic remission was 35.8% for SKYRIZI SC and 9.1% for placebo in the overall population.
  • 3At week 24, ulcer-free endoscopy was 36.6% for SKYRIZI SC and 9.1% for placebo in the overall population.
  • 4Subcutaneous induction treatment was under review by the U.S. Food and Drug Administration and European Medicines Agency.
  • 5The trial included patients with moderately to severely active Crohn’s disease, and 65% had previously experienced an inadequate response to advanced therapies.
  • The materials report different ABBV share-price reactions after the data release, including a decline and a subsequent rise, without a single consistent time reference.

Sources